Muscarinic Receptor Antagonism: revefenacin selectively antagonizes the M3 subtype of muscarinic receptors in the airway smooth muscles. By blocking these receptors, it inhibits the binding of acetylcholine, a neurotransmitter, thereby preventing its broncho-constrictive effects.
Bronchodilation: By blocking the M3 receptors, revefenacin relaxes the smooth muscles surrounding the airways, leading to bronchodilation. This helps to alleviate bronchoconstriction, improve airflow, and reduce symptoms in patients with COPD.
Spectrum of Activity:
Chronic Obstructive Pulmonary Disease (COPD): revefenacin is especially prescribed for the maintenance therapy of COPD patients. It is used to prevent and treat COPD symptoms such as shortness of breath, coughing,chest tightness and wheezing.
Extended Duration of Action: revefenacin is formulated as a once-daily inhaled medication, providing a sustained effect throughout the day. Its prolonged action duration helps maintain bronchodilation and symptom control, reducing the need for frequent dosing.
